In vitro effect of GF120918, a novel reversal agent of multidrug resistance, on acute leukemia and multiple myeloma cells

Leukemia

Volumn 10, Issue 12, 1996, Pages 1930-1936

  Den Ouden, D ^a   Van Den Heuvel, M ^a   Schoester, M ^a   Van Rens, C ^a   Sonneveld, P ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Acute myeloid leukemia; GF120918; Multiple drug resistance; Multiple myeloma; P glycoprotein

Indexed keywords

ACRIDINE DERIVATIVE; ANTINEOPLASTIC AGENT; CD34 ANTIGEN; DOXORUBICIN; ELACRIDAR; GLYCOPROTEIN P; RHODAMINE 123; UNCLASSIFIED DRUG;

ACUTE LEUKEMIA; ARTICLE; BLAST CELL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG TRANSPORT; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; MULTIDRUG RESISTANCE; MULTIPLE MYELOMA; PRIORITY JOURNAL;

EID: 0030475859     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Epstein J, Xiao HQ, Oba BK. P-glycoprotein expression in plasma-cell myeloma is associated with resistance to VAD. Blood 1989; 74: 913-917.
2. Kartner N, Riordan JR, Ling V. Cell surface P-glycoprotein associated with multidrug resistance in mammalian cell lines. Science 1983; 221: 1285-1288.
3. Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary. Biochim Biophys Acta 1976; 455: 152-162.
4. Riordan JR, Ling V. Genetic and biochemical characterization of multidrug resistance. Pharmacol Ther 1985; 28: 51-65.
5. Gerlach JH, Endicott JA, Juranka PF et al. Homology between P-glycoprotein and a bacterial haemolysin transport protein suggests a model for multidrug resistance. Nature 1986; 324: 485-489.
6. Horio M, Gottesman MM, Pastan I. ATP-dependent transport of vinblastine in vesicles from human multidrug-resistant cells. Proc Natl Acad Sci USA 1988; 85: 3580-3584.
7. Pirker R, Wallner J, Geissler K, Linkesch W, Haas OA, Bettelheim P, Hopfner M, Scherrer R, Valent P, Havelec L et al. MDR1 gene expression and treatment outcome in acute myeloid leukemia. J Natl Cancer Inst 1991; 83: 708-712.
8. te Boekhorst PA, de Leeuw K, Schoester M, Wittebol S, Nooter K, Hagemeijer A, Lowenberg B, Sonneveld P. Predominance of functional multidrug resistance (MDR-1) phenotype in CD34 acute myeloid leukemia cells. Blood 1993; 82: 3157-3162.
9. Campos L, Guyotat D, Archimbaud E, Calmard-Oriol P, Tsuruo T, Troncy J, Treille D, Fiere D. Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis. Blood 1992; 79: 473-476.
10. Sonneveld P, Schoester M, de Leeuw K. Clinical modulation of multidrug resistance in multiple myeloma: effect of cyclosporine on resistant tumor cells. J Clin Oncol 1994; 12: 1584-1591.
11. Marie JP, Faussat-Suberville AM, Zhou D, Zittoun R. Daunorubicin uptake by leukemic cells: correlations with treatment outcome and mdr1 expression. Leukemia 1993; 7: 825-829.
12. Nooter K, Sonneveld P, Oostrum R, Herweijer H, Hagenbeek T, Valerio D. Overexpression of the mdr1 gene in blast cells from patients with acute myelocytic leukemia is associated with decreased anthracycline accumulation that can be restored by cyclosporin-A. Int J Cancer 1990; 45: 263-268.
13. Dalton WS, Grogan TM, Rybski JA, Scheper RJ, Richter L, Kailey J, Broxterman HJ, Pinedo HM, Salmon SE. Immunohistochemical detection and quantitation of P-glycoprotein in multiple drug-resistant human myeloma cells: association with level of drug resistance and drug accumulation. Blood 1989; 73: 747-752.
14. Arceci RJ. Clinical significance of P-glycoprotein in multidrug resistance malignancies. Blood 1993; 81: 2215-2222.
15. Lamy T, Goasguen JE, Mordelet E, Grulois I, Dauriac C, Drenou B, Chaperon J, Fauchet R, le Prise PY. P-glycoprotein (P-170) and CD34 expression in adult acute myeloid leukemia (AML). Leukemia 1994; 8: 1879-1883.
16. Zhou DC, Marie JP, Suberville AM, Zittoun R. Relevance of mdr1 gene expression in acute myeloid leukemia and comparison of different diagnostic methods. Leukemia 1992; 6: 879-885.
17. Guerci A, Merlin JL, Missoum N, Feldmann L, Marchal S, Witz F, Rose C, Guerci O. Predictive value for treatment outcome in acute myeloid leukemia of cellular daunorubicin accumulation and P-glycoprotein expression simultaneously determined by flow cytometry. Blood 1995; 85: 2147-2153.
18. te Boekhorst PAW, Lowenberg B, van Kapel J, Nooter K, Sonneveld P. Multidrug resistant cells with high proliferative capacity determine response to therapy in acute myeloid leukemia. Leukemia 1995; 9: 1025-1031.
19. Beck WT, Cirtain MC, Look AT, Ashmun RA. Reversal of Vinca alkaloid resistance but not multiple drug resistance in human leukemic cells by verapamil. Cancer Res 1986; 46: 778-784.
20. Greenberger LM, Lisanti CJ, Silva JT, Horwitz SB. Domain mapping of the photoaffinity drug-binding sites in P-glycoprotein encoded by mouse mdr1b. J Biol Chem 1991; 266: 20744-20751.
21. Ross DD, Wooten PJ, Sridhara R, Ordonez JV, Lee EJ, Schiffer CA. Enhancement of daunorubicin accumulation, retention and cytotoxicity by verapamil or cyclosporin A in blast cells from patients with previously untreated acute myeloid leukemia. Blood 1993; 82: 1288-1299.
22. Salmon SE, Dalton WS, Grogan TM, Plezia P, Lehnert M, Roe DJ, Miller TP. Multidrug-resistant myeloma: laboratory and clinical effects of verapamil as a chemosensitizer. Blood 1991; 78: 44-50.
23. Dalton WS, Grogan TM, Meltzer PS, Scheper RJ, Durie BG, Taylor CW, Miller TP, Salmon SE. Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy. J Clin Oncol 1989; 7: 415-424.
24. Sonneveld P, Durie BG, Lokhorst HM, Marie JP, Solbu G, Suciu S, Zittoun R, Lowenberg B, Nooter K. Modulation of multidrug-resistant multiple myeloma by cyclosporin. The Leukaemia Group of the EORTC and the HOVON. Lancet 1992; 340: 255-259.
25. Hyafill F, Vergely C, Du Vignaud P, Grand-Perret T. In vitro and in vivo reversal of multidrug resistance by CF120918, an acridine carboxamide derivative. Cancer Res 1993; 53: 4595-4602.
26. Dalton WS, Durie BG, Alberts DS, Gerlach JH, Cress AE. Characterization of a new drug-resistant human myeloma cell line that expresses P-glycoprotein. Cancer Res 1986; 46: 5125-5130.
27. Chaudhary PM, Roninson IB. Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells. Cell 1991; 66: 85-94.
28. Ludescher C, Thaler J, Drach D, Drach J, Spitaler M, Gattringer C, Huber H, Hofmann J. Detection of activity of P-glycoprotein in human tumour samples using rhodamine 123. Br J Haematol 1992; 82: 161-165.
29. Futscher BW, Blake LL, Gerlach JH, Grogan TM, Dalton WS. Quantitative polymerase chain reaction analysis of mdr1 mRNA in multiple myeloma cell lines and clinical specimens. Anal Biochem 1993; 213: 414-421.
30. Broxterman HJ, Sonneveld P, Feller N, Ossenkoppele GJ, Wahrer DCR, Eekman CA, Schoester M, Lankelma J, Pinedo HM, Lowen-berg B, Schuurhuis GJ. Quality control of multidrug resistance assays in adult acute leukemia: correlation between assays for P-glycoprotein and activity. Blood 1996; 87: 4809-4816.
31. Twentyman PR, Rhodes T, Rayner S. A comparison of rhodamine 123 accumulation and efflux in cells with P-glycoprotein-mediated and MRP-associated multidrug resistance phenotypes. Eur J Cancer 1994; 9: 1360-1369.
32. List AF, Spier C, Greer J, Wolff S, Hutter J, Dorr R, Salmon S, Futscher B, Baier M, Dalton W. Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia. J Clin Oncol 1993; 11: 1652-1660.
33. Marie JP, Helou C, Thevenin D, Delmer A, Zittoun R. In vitro effect of P-glycoprotein (P-gp) modulators on drug sensitivity of leukemic progenitors (CFU-L) in acute myelogenous leukemia (AML). Exp Hematol 1992; 20: 565-568.